Baudax Bio Stock News

A 1-for-35 reverse stock split of Baudax Bio Inc (NASDAQ: BXRX) has gone into effect. These are the details.

Baudax Bio (BXRX) announced that the company''s board has approved a 1-for-35 reverse stock split of its common shares

Are these penny stocks on your watchlist for next week? The post Can These Penny Stocks Climb This Week?

Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

MALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today ann

Baudax Bio Inc (BXRX) shares closed today 21.9% lower than it did at the end of yesterday. The stock is currently down 75.4% year-to-date, down 75.9% over the past 12 months, and down 94.5% over the past five years. Today, the Dow Jones Industrial Average rose 0.3%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $0.36 and as low as $0.24 this week.Shares closed 88.3% below its 52-week high and 5.3% above its 52-week low.Trading volume this week was 51.1% lower than the 10-day average and 18.1% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 153.7% The company's stock price performance over the past 12 months lags the peer average by 142.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

State Street Corp acquired a new stake in Baudax Bio, Inc. (NASDAQ:BXRX) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 284,553 shares of the companys stock, valued at approximately $216,000. State Street Corp owned 0.34% of Baudax Bio at the []

Baudax Bio, Inc. (BXRX) with the stream of -5.17% also noticed, India iFresh Inc. (IFMK) encountered a rapid change of -92.62% in the last hour of trading session. Baudax Bio, The post Up to Date Stock in scrutiny: Baudax Bio, Inc. (NASDAQ:BXRX), iFresh Inc. (NASDAQ:IFMK) appeared first on Stocks Equity .

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced Gerri Henwood, the Companys President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held November 29 December 2, 2021.

Baudax Bio, Inc. (BXRX) CEO Gerri Henwoodon Q3 2021 Results - Earnings Call Transcript

MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today an

MALVERN, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today an

MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today a

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today a